// App-Quantinova.ai

3013 : Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC).

Researchers

Presenter

  • Michael B. Atkins

Principal Investigators

  • F. Stephen Hodi

  • John A. Thompson

  • David F. McDermott

  • Wen-Jen Hwu

  • Donald P. Lawrence

  • Nancy Ann Dawson

  • Deborah Jean Lee Wong

  • Shailender Bhatia

  • Marihella James

  • Xinxin Shu

  • Rodolfo F. Perini

  • Nageatte Ibrahim

  • Antoni Ribas

  • Toni K. Choueiri

Medical Centers

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • Dana-Farber Cancer Institute, Boston, MA

  • Seattle Cancer Care Alliance, Seattle, WA

  • Beth Israel Deaconess Medical Center, Boston, MA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Massachusetts General Hospital/Dana-Farber Cancer Institute, Boston, MA

  • Lombardi Comprehensive Cancer Center, Washington, DC

  • Ronald Reagan UCLA Medical Center, Los Angeles, CA

  • University of Washington Seattle Cancer Care Alliance, Seattle, WA

  • Merck & Co., Inc., Kenilworth, NJ

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • Dana-Farber/Brigham and Women's Cancer Center, Boston, MA

Locations

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

  • Melanoma

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pegylated interferon alfa-2b

  • Pembrolizumab

  • Ipilimumab

  • Interferon

  • PEG-IFN

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02089685

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved